SCHEMBL20028588

SCHEMBL20028588

Cc1cc(C(=O)NC(Cc2ccccc2)C(=O)C(N)=O)n(-c2ccccc2)n1

nearest known ligand 0.54

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 11/20 0.54
ALDH1A1 P00352 1/20 0.53
MAPT P10636 1/20 0.52
TSHR P16473 1/20 0.50
CTSS P25774 1/20 0.50
SMYD3 Q9H7B4 1/20 0.49
KMT2A Q03164 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23268997 1.00 CAPN1 (0.54) CAPN1ALDH1A1MAPTTSHRCTSS
SCHEMBL20028561 0.95 CAPN1 (0.54) CAPN1ALDH1A1MAPT
SCHEMBL21854059 0.95 CAPN1 (0.54) CAPN1ALDH1A1MAPT
SCHEMBL21854326 0.94 CAPN1 (0.51) CAPN1ALDH1A1MAPTCTSS
SCHEMBL20027837 0.94 CAPN1 (0.51) CAPN1ALDH1A1MAPTCTSS
SCHEMBL21854108 0.93 CAPN1 (0.52) CAPN1ALDH1A1MAPTCTSS
SCHEMBL20027684 0.93 CAPN1 (0.52) CAPN1ALDH1A1MAPTCTSS
SCHEMBL21854041 0.92 MAPT (0.52) CAPN1ALDH1A1MAPTCTSS
SCHEMBL20027971 0.92 MAPT (0.52) CAPN1ALDH1A1MAPTCTSS
SCHEMBL21854307 0.92 CAPN1 (0.49) CAPN1ALDH1A1MAPTCTSSKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-20210113560-A1 METHOD OF TREATING FIBROTIC DISEASE BLADE THERAPEUTICS INC (US) 2021-04-22 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 CAPN1 3/4885ALDH1A1 4193/4885MAPT 562/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 CAPN1 4/4885ALDH1A1 4421/4885MAPT 330/4885
US-20210113560-A1 METHOD OF TREATING FIBROTIC DISEASE CAPN9, CAPNS1, CAPN1 CAPN1 3/4885ALDH1A1 1657/4885MAPT 2905/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 CAPN1 3/4885ALDH1A1 4193/4885MAPT 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.